A process for purifying eslicarbazepine acetate is provided The crystalline particles of eslicarbazepine acetate having a median particle size between 5 µm and 20 µm and a specific surface area of from 0.1 m2/g to 10 m2/g as measured by B.E.T. method are obtained Eslicarbazepine acetate having purity greater than 99.0% as measured by high performance liquid chromatography and a pharmaceutical composition containing the same are also provided.
